EULAR: Positive Ph III sarilumab data in RA from Sanofi and Regeneron

French drug major Sanofi (Euronext: SAN) and partner US biotech firm Regeneron Pharmaceuticals (Nasdaq: REGN) have presented positive results from a Phase III trial of their investigational drug sarilumab in rheumatoid arthritis (RA) patients who were inadequate responders to methotrexate (MTX) therapy.

New data, presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) Congress in Paris, France, showed that sarilumab increased major clinical response rates defined as achieving an ACR70 for at least 24 consecutive weeks and showed sustained improvement in signs and symptoms of RA after 52 weeks, which were secondary endpoints of the trial.

As previously announced, in this study, called SARIL-RA-MOBILITY, sarilumab met all three co-primary endpoints, demonstrating improvement in disease signs and symptoms at 24 weeks, physical function at 16 weeks and inhibition of joint damage progression at 52 weeks